Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most populous nation.

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, improving satiety and reducing cravings for food, eventually inducing weight loss.

Wegovy, which is a prescription medicine is indicated to help manage weight and lower the risk of serious heart-related events in adults with established cardiovascular diseases. From cost to availabi